Welcome to our dedicated page for NextPlat SEC filings (Ticker: NXPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NextPlat Corp (NASDAQ: NXPL, NXPLW) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detail on its healthcare, communications and e-commerce activities, as well as its corporate governance and listing status. These SEC filings, including current reports on Form 8-K, offer insight into material events such as leadership changes, compensation arrangements, financial results announcements and communications with the Nasdaq Stock Market about listing requirements.
Recent 8-K filings describe matters such as the appointment of a new Chief Financial Officer, amendments to the Chief Executive Officer’s employment agreement and compensation, and notices from Nasdaq regarding the company’s compliance with the minimum bid price requirement. Other filings reference press releases that announce quarterly financial results and provide operational updates across NextPlat’s healthcare services, satellite-enabled communications and e-commerce development programs.
On this page, users can review NextPlat’s SEC filings to understand how the company reports its business segments, material contracts, and significant corporate actions. Forms such as 10-K annual reports and 10-Q quarterly reports, when available, typically contain segment information, risk factor discussions and management’s analysis of operations. Current reports on Form 8-K document specific events, while other filings may address equity incentive plans, executive compensation and governance matters.
Stock Titan enhances access to these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers interpret complex disclosures. Real-time updates from the SEC’s EDGAR system ensure that new NextPlat filings appear promptly, and users can also review Form 4 insider transaction reports when they are filed to see reported purchases, sales or grants of company securities by officers, directors and significant shareholders. This combination of primary filings and AI-generated insights can help investors and researchers analyze NextPlat’s regulatory disclosures more efficiently.
NextPlat Corp filed a registration statement to register for resale up to 2,647,674 shares of its common stock by selling securityholders. These shares were acquired in private placements between 2019 and 2023 and the company will receive no proceeds from resale by the selling holders.
The filing follows a 1-for-10 reverse stock split effective April 13, 2026, which reduced the number of shares outstanding to approximately 2.7 million. The company’s common stock trades on The Nasdaq Capital Market under the symbol NXPL.
NextPlat Corp is holding a virtual 2026 Annual Meeting of Stockholders on June 24, 2026 at 10:00 a.m. Eastern Daylight Time as a listen-only conference call and webcast. Holders of 2,708,507 shares of common stock as of April 27, 2026 may vote.
Stockholders will elect six directors, ratify RBSM LLP as independent auditor for 2026, approve on an advisory basis executive compensation, and authorize potential adjournment to solicit more proxies. The Board recommends voting “FOR” all director nominees and each proposal.
The Board has six members, four deemed independent under Nasdaq rules, with separate Audit, Compensation and Nominating Committees. Pay disclosures show 2025 total compensation of $652,980 for CEO David Phipps and $265,750 for CFO Amanda Ferrio, along with equity incentive plans and detailed severance terms.
NextPlat Corp shared preliminary expectations for its first quarter 2026 results, pointing to a continuing turnaround driven mainly by contracted healthcare services. The company expects Q1 2026 gross margins to rise to 34+% and operating expenses to decline by 8+% from Q4 2025.
First quarter consolidated gross profit is expected to increase by about 40% versus Q4 2025 as the business shifts toward higher-margin contracted healthcare revenue. NextPlat also reports a record number of added 340B entities, supporting anticipated healthcare services revenue growth and margin expansion through 2026, and is targeting positive operating income in the third quarter.
NextPlat Corp has regained compliance with Nasdaq’s minimum bid price rules, removing a prior delisting risk. The company had previously been notified that its stock traded below $1.00 for 30 straight trading days, triggering a grace period to cure the deficiency.
Nasdaq later confirmed that, for the 10 consecutive business days from April 13, 2026 to April 24, 2026, NextPlat’s closing bid price was at or above $1.00 per share. As a result, Nasdaq issued a compliance letter on April 27, 2026, closed the matter, and NextPlat remains listed on The Nasdaq Capital Market under the ticker “NXPL”.
NextPlat Corp director Anthony Armas, through Apollo Two MSO, LLC, reported an indirect acquisition of Common Stock as a compensation-related grant. The entity received 12,162 shares of NextPlat Common Stock at a stated price of $0.00 per share, characterized as a grant or award.
Following this transaction, Apollo Two MSO, LLC’s indirect holdings associated with Armas increased to 113,316 shares of Common Stock. The filing reflects a non-market, award-type acquisition rather than an open-market purchase or sale.
NextPlat Corp director Rodney Barreto received a stock grant that increased his direct ownership. On April 6, 2026, he was awarded 24,324 shares of NextPlat common stock at no stated purchase price. After this grant, his direct holdings rose to 469,909 common shares, reflecting a routine compensation-related acquisition rather than an open-market purchase.
ELLENOFF DOUGLAS reported acquisition or exercise transactions in this Form 4 filing.
NextPlat Corp director Douglas Ellenoff received a grant of 24,324 shares of NextPlat common stock on April 6, 2026. The shares were awarded at no cash cost per share, reflecting equity compensation rather than an open‑market purchase. Following this award, Ellenoff directly owns 190,500 NextPlat common shares.
NextPlat Corp is implementing a 1-for-10 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on April 13, 2026. Every 10 existing shares will be combined into 1 share, with par value staying at $0.0001.
The reverse split will reduce outstanding common shares from approximately 26.9 million to approximately 2.7 million, while authorized shares remain at 50 million. Stock options, warrants and equity plan reserves will be adjusted proportionately, increasing exercise prices and reducing underlying share amounts. No fractional shares will be issued; instead, holders will receive cash based on the Nasdaq closing price on the effective date.
NextPlat’s stock is expected to begin trading on a split-adjusted basis on April 13, 2026 under the symbol “NXPL” with a new CUSIP number. Historical per-share figures, including net loss per share, have been recast to reflect the new share count for 2025 and 2024.
NextPlat Corp reported full-year 2025 revenue of approximately $54.3 million, down 18% from about $66.1 million in 2024, as healthcare prescription volumes declined but e-commerce grew modestly. Healthcare revenue fell to $39.7 million from $52.3 million, driven by fewer prescriptions and lower 340B contract revenue, partly offset by higher reimbursement per script.
e-Commerce revenue increased to $14.6 million from $13.8 million on stronger airtime and hardware sales and favorable foreign exchange. Overall gross margin declined to about 20% from 26%, but total operating expenses were cut roughly in half to $19.9 million from $40.0 million, reflecting cost reductions and the absence of a prior-year impairment loss. Net loss attributable to common stockholders narrowed to approximately $11.7 million, or $0.44 per share, from $13.4 million, or $0.65 per share. The company ended 2025 with about $13.7 million in cash and roughly $15.0 million in working capital.